|
業務類別
|
Biotechnology |
|
業務概覽
|
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigationin other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients. |
| 公司地址
| 11055 Flintkote Avenue, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 952-7570 |
| 傳真號碼
| +1 858 952-7571 |
| 公司網頁
| https://www.cardiffoncology.com |
| 員工數量
| 31 |
| Mr. Joshua Muntner |
Chief Financial Officer |
-- |
09/04/2026 |
| Dr. Mani Mohindru, PhD |
Director, President and Chief Executive Officer |
-- |
09/04/2026 |
| Ms. Brigitte Lindsay |
Chief Accounting Officer |
-- |
27/01/2026 |
| Dr. Tod Smeal, PhD |
Chief Scientific Officer |
-- |
23/04/2026 |
| Dr. Roger Sidhu |
Chief Medical Officer |
美元 279.37K |
23/04/2026 |
| Dr. Ajay Aggarwal, M.D. |
Chief Operating Officer |
-- |
09/04/2026 |
|
|
| Dr. Gary W. Pace,PhD |
Independent Director |
23/04/2026 |
| Dr. James O. Armitage,M.D. |
Independent Director |
23/04/2026 |
| Dr. Rodney S. Markin,M.D.,PhD |
Chairman of the Board |
23/04/2026 |
| Dr. Renee P. Tannenbaum, D.Pharm. |
Independent Director |
23/04/2026 |
| Ms. Lale White |
Independent Director |
23/04/2026 |
| Dr. Mani Mohindru, PhD |
Director, President and Chief Executive Officer |
09/04/2026 |
|
|
|
|
